Surprising it may sound- however, a latest iatrogenic etiology for heart disease in women has been described in American Heart Association’s Journal “Circulation”. The published research described that some therapies for breast cancer rather increases the risk of a host of heart diseases in women (especially above 65 years of age). The research found that: HER-2 targeted therapy (with monoclonal antibody) for breast cancer can weaken heart muscles (temporary or permanent) leading to a risk of heart failure. Doxorubicin chemotherapy for breast cancer and damage heart cells.
The risks are higher if the drug is administered at once and the risks are lower if it is administered slowly. Co-administration of dexrazoxane can reduce doxorubicin-induced heart damage. Source: Laxmi S et al, Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the…
